FDA accepts second generic tirzepatide application, from Amneal and Adalvo
The FDA accepted a second generic tirzepatide application, from Amneal and Adalvo, but Lilly's patents point to market availability around 2036 to 2038.
On July 8, 2026, Amneal Pharmaceuticals and its partner Adalvo said the FDA accepted two abbreviated new drug applications, or ANDAs, for a generic version of tirzepatide delivered by autoinjector [1]. Nine days earlier, on June 29, 2026, Sandoz announced the FDA had accepted two ANDAs of its own, one matching the Mounjaro type 2 diabetes indication and one matching the Zepbound obesity indication [1]. That is four accepted applications from two companies in under two weeks, and the first real generic pipeline for the molecule [1].
The word that matters is "accepted." Acceptance means the FDA checked the paperwork, found it complete enough to evaluate, and put it in the queue [1]. It is not approval. The agency has not yet decided whether either product is bioequivalent to the brand drug or whether its manufacturing meets standards [1]. The FDA's typical ANDA review window runs about 10 months, and for a first generic peptide packaged in an injector device that timeline is likely to run longer, because the agency also has to assess whether the device performs like Eli Lilly's pen [1]. Nothing has been approved, and nothing is for sale [1].
Tirzepatide is the molecule in Mounjaro and Zepbound, and it outsold every other drug in the world in 2025 [1].
The patent calendar outlasts the FDA calendar
An FDA approval would not by itself put a generic tirzepatide on pharmacy shelves [1]. Lilly holds patents on the tirzepatide molecule and separate patents on the formulation and the autoinjector pen [1]. The core compound patent is generally tracked to expire around January 2036, and device and formulation patents could extend exclusivity into 2039 or later, according to patent trackers [1]. Estimates of when a generic could actually reach the market cluster around 2036 to 2038 [1].
A generic maker has two routes around a patent that has not expired: win a Paragraph IV challenge in court by arguing the patent is invalid or would not be infringed, or negotiate a licensed early entry with the brand company, the path several insulin generics eventually took [1]. Neither is quick and neither is guaranteed [1]. Until one happens, an approved ANDA waits next to Lilly's patent portfolio rather than in a pharmacy [1].
Generic and compounded tirzepatide are different paths
Compounded tirzepatide is made by a pharmacy for an individual patient and was never required to prove bioequivalence to the FDA [1]. That route narrowed sharply after the FDA resolved the tirzepatide shortage in March 2025 and later moved to formally exclude tirzepatide from the 503B bulk substances list [1]. A generic follows the opposite path: a fully FDA-regulated copy tested for bioequivalence and sold under the same regulatory umbrella as Zepbound itself [1].
Why it matters for patients
Nothing about the cost of tirzepatide changes this year [1]. The options available now are the same ones that existed before these filings: Zepbound through LillyDirect's self-pay program at $299 to $449 a month depending on dose; Medicare Part D coverage at $50 a month through the Bridge program that began July 1, 2026; or a narrow compounded option for patients with a documented medical reason [1]. Neither Sandoz nor Amneal has disclosed pricing or launch strategy, which is not surprising this early [1].
The practical point is about time frames. For anyone budgeting around the moment tirzepatide becomes meaningfully cheaper through the generic system rather than through a coverage program, the number to plan around is the 2036 to 2038 window cited by patent trackers, not the FDA's current review queue [1].
What happens next
Three developments would move the timeline [1]. A Paragraph IV patent challenge from either company would be the largest, since a court ruling against Lilly's patents could open the door years early [1]. An FDA decision on either ANDA, expected sometime in 2027 given the roughly 10-month review clock, would confirm the applications are technically viable even if a launch remains blocked [1]. And any signal that Lilly is negotiating a licensed early-entry deal would be the clearest sign a launch date is moving up [1]. None of that has happened yet [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.